



## Influenza B/Yamagata Update

**Lisa Grohskopf, MD, MPH**

Advisory Committee on Immunization Practices

February 28, 2024

# Influenza B/Yamagata and 2024-25 Influenza Vaccines

- Quadrivalent influenza vaccines introduced in 2013-14 to provide broader coverage of influenza B viruses.
  - Quadrivalents contain one influenza B virus from each lineage (Victoria and Yamagata).
  - Transition from trivalents to quadrivalents complete by the 2021-22 influenza season.
- No confirmed influenza B/Yamagata viruses in global surveillance since March 2020.
- WHO and the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) have recommended excluding B/Yamagata from influenza vaccines.
- WHO has made recommendations for Northern Hemisphere 2024-25 vaccines.
  - Decisions regarding composition are made by individual national regulatory authorities.
- VRBPAC to discuss composition of 2024-25 U.S. influenza vaccines on March 5, 2024.

[Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season \(who.int\)](#)

[Vaccines and Related Biological Products Advisory Committee October 5, 2023 Meeting Announcement - 10/05/2023 | FDA](#)

[Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season \(who.int\)](#)

[Vaccines and Related Biological Products Advisory Committee March 5, 2024 Meeting Announcement - 03/05/2024 | FDA](#)

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

